利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.024 秒)

    Ischemic tissue cell therapy
    43.
    发明授权
    Ischemic tissue cell therapy 有权

    公开(公告)号：US10335434B2

    公开(公告)日：2019-07-02

    申请号：US14336621

    申请日：2014-07-21

    申请人： Paul R. Sanberg ,  Alison E. Willing

    发明人： Paul R. Sanberg ,  Alison E. Willing

    IPC分类号： A61K35/15 ,  A61K35/51 ,  A61K35/12 ,  A61K35/44 ,  C12N5/078 ,  C12N5/0786

    摘要： The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.

    HUCBC TREATMENT OF AMYLOID-ASSOCIATED DISEASE
    44.
    发明申请
    HUCBC TREATMENT OF AMYLOID-ASSOCIATED DISEASE 审中-公开

    公开(公告)号：US20180325950A1

    公开(公告)日：2018-11-15

    申请号：US16035936

    申请日：2018-07-16

    申请人： Jun Tan ,  Paul R. Sanberg

    发明人： Jun Tan ,  Paul R. Sanberg

    IPC分类号： A61K35/16 ,  A61K35/44 ,  A61K35/12

    CPC分类号： A61K35/16 ,  A61K35/44 ,  A61K2035/122

    摘要： Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid angiopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.

    HUCBC treatment of amyloid-associated disease
    45.
    发明授权
    HUCBC treatment of amyloid-associated disease 有权

    公开(公告)号：US10039785B2

    公开(公告)日：2018-08-07

    申请号：US15195243

    申请日：2016-06-28

    申请人： Jun Tan ,  Paul R. Sanberg

    发明人： Jun Tan ,  Paul R. Sanberg

    IPC分类号： A61K35/12 ,  A61K35/16 ,  A61K35/44

    摘要： Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.